# Climb Bio Reports Early Phase 2 Budoprutug Signals in Primary Membranous Nephropathy > Climb Bio reported Phase 2 budoprutug data in pMN, with B-cell depletion and immunologic remission at 12 weeks on 200 mg and deeper depletion at 600 mg. - Published: 2026-10-24T23:55:26+00:00 - Section: Research & Clinical Trials - Author: News Desk - URL: https://newsforagent.com/news/2026-10-24/climb-bio-phase-2-budoprutug-pmn - Source: [TradingView](https://www.tradingview.com/news/tradingview:7da5e35014d36:0-climb-bio-inc-clym-reports-early-phase-2-signals-in-pmn/) ## Key takeaways - Climb Bio reported B-cell depletion, PLA2R antibody reduction and immunologic remission at 12 weeks with 200 mg budoprutug in primary membranous nephropathy. - Early 600 mg data suggest greater exposure and deeper B-cell depletion than the 200 mg dose. - Both budoprutug doses were generally well tolerated to Week 12 and Week 6. [Climb Bio](https://akta.pro/company-profiles/0003fqs/climb-bio) reported initial Phase 2 data showing B-cell depletion, PLA2R antibody reduction and immunologic remission at 12 weeks with 200 mg budoprutug in primary membranous nephropathy, with early 600 mg data suggesting greater exposure and deeper depletion. [TradingView](https://www.tradingview.com/news/tradingview:7da5e35014d36:0-climb-bio-inc-clym-reports-early-phase-2-signals-in-pmn/) carried the report, based on the company's press release distributed by GlobeNewswire. ## What the Phase 2 Budoprutug Data Showed The 200 mg cohort showed B-cell depletion at 12 weeks, which the report describes as confirming target engagement. PLA2R antibody reductions were also seen at 12 weeks on 200 mg, a biomarker the report links to later proteinuria improvements. Immunologic remission at 12 weeks was recorded in the 200 mg cohort. Early data from the 600 mg dose suggest greater exposure and deeper depletion than 200 mg, pointing to a dose response. Both doses were generally well tolerated to Week 12 and Week 6, which the report says supports continued dose escalation and enrollment. A case in minimal change disease showed three-year steroid-free remission, which the report describes as a hint at broader utility beyond pMN. The readout is an early Phase 2 result building on Phase 1b. The report states that a larger catalyst would require sustained responses, proteinuria improvements, higher-dose cohort outcomes and longer follow-up data in 2027. ## Climb Bio's Clinical and Funding Record Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody therapies for B-cell mediated rare kidney and autoimmune diseases, according to akta.pro [company records](https://akta.pro/company-data). The same records list budoprutug as an anti-CD19 antibody and CLYM116 as an anti-APRIL antibody, with the company pre-revenue and funded by equity. In April 2026, Climb Bio entered a securities purchase agreement for a $110 million private placement at $9.50 per share plus pre-funded warrants, covering 9,481,000 shares and pre-funded warrants for an additional 2,106,000 shares. The company reported $160.7 million in cash, cash equivalents and marketable securities as of December 31, 2025, sufficient to fund operations into 2028. Its partner Beijing Mabworks Biotech initiated a Phase 1/2 study of CLYM116 and expects to begin dosing in IgAN patients in the third quarter of 2026, with Climb Bio holding worldwide rights outside Greater China. ## Earlier Budoprutug and Financial Milestones In May 2026, Climb Bio said it would present clinical data from its Phase 1b/2a trial of budoprutug in primary immune thrombocytopenia at the European Hematology Association 2026 Congress in Stockholm, Sweden, scheduled for June 11-14, 2026, Stock Titan reported. In June 2026, the company announced initial Phase 1b data demonstrating on-target clinical activity for budoprutug in immune thrombocytopenia at that congress. In August 2026, Climb Bio reported quarterly earnings of ($0.18) per share, beating the consensus estimate of ($0.21) by $0.03, according to Ticker Report. Simply Wall St reported that the company posted a net loss of US$13.5 million for the second quarter and US$27.22 million for the first half of 2026. ## What Comes Next for the Program Beijing Mabworks Biotech expects to initiate dosing of CLYM116 in IgAN patients in the third quarter of 2026. Longer follow-up data from the budoprutug program are expected in 2027. ## Companies in this story - [Climb Bio company profile](https://akta.pro/company-profiles/0003fqs/climb-bio) · website: https://climbbio.com --- News for Agent · https://newsforagent.com/llms.txt